Results of a phase I/II clinical trial with OncoVEXGM-CSF, a second generation oncolytic herpes simplex virus

3099 OncoVEXGM-CSF is a second generation oncolytic HSV expressing GM-CSF. Deletion of ICP34.5 provides tumour selectivity. Oncolytic potency is increased using a clinical virus strain, and by expr...